Date: 2015-12-19
Type of information: Nomination
Compound:
Company: Alnylam Therapeutics (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 19, 2015, Alnylam Pharmaceuticals, a leading RNAi therapeutics company, announced that Michael Bonney , current Board member and former chief executive of Cubist Pharmaceuticals , has been appointed as Chairman effective January 1, 2016 . Founding investor and current Chairman John Clarke will remain on the Board as a Director. Alnylam also announced that David Pyott has been elected to the company\'s Board. Mr. Pyott is former chairman and Chief Executive Officer of Allergan and will join the Alnylam Board effective immediately. Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (Cubist, a subsidiary of Merck & Co., Inc. as of January 2015 ) from June 2003 until his retirement on December 31, 2014 . From January 2002 to June 2003 , Mr. Bonney served as Cubist\'s President and Chief Operating Officer, and from 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc. Prior to joining Biogen, Mr. Bonney held various positions at Zeneca Pharmaceuticals . Since 2014, Mr. Bonney has been a Director of Alnylam Pharmaceuticals, Inc. and serves on the audit committee. Mr. Bonney is a Director of the Celgene Corporation, the Whitehead Institute for Biomedical Research , and the Gulf of Maine Research Institute, and was a Director of NPS Pharmaceuticals, Inc. until its sale to Shire plc in February 2015 , where he was a member of the audit and compensation committees and chaired the governance committee. He chairs the board of trustees of Bates College and is also a trustee of the Tekla complex of life sciences and healthcare dedicated funds, where he serves on the valuation committee and chairs the governance and nominating committees. Mr. Bonney received a B.A. in Economics from Bates College . Mr. Pyott served as CEO of Allergan from 1998 to 2015, where he was recognized by the Harvard Business Review as one of \"The 100 Best Performing CEO\'s in the World.\" During his tenure, Allergan became the fastest growing ophthalmic company, and a global leader in medical aesthetics, medical dermatology, neurology, and urology. Prior to Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland -based Novartis AG. Mr. Pyott is Lead Director and a member of the Board of Directors of Avery Dennison Corporation and a member of the Supervisory Board of Royal Philips in the Netherlands . He is Vice Chairman of the Board of Trustees of Chapman University , a member of the Governing Board of the London Business School , President of the International Council of Ophthalmology Foundation , and a member of the Advisory Board of the Foundation of the American Academy of Ophthalmology. Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam , a Master of Arts degree from the University of Edinburgh , and a Master of Business Administration degree from the London Business School .
Mr. Pyott\'s appointment brings Alnylam\'s Board to eleven members, of which ten are independent.
Financial terms:
Latest news:
